Resources from the same session
1020MO - AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
Presenter: Feng Wang
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1021MO - Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
Presenter: Meredith Mckean
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 1020MO and 1021MO
Presenter: Alessandra Curioni-Fontecedro
Session: Mini oral session - Investigational immunotherapy
Resources:
Slides
Webcast
1022MO - Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans
Presenter: Lama Dawi
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1023MO - Decoding immunotherapy resistance: A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes
Presenter: Kinga Bernatowicz
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1024MO - Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy
Presenter: Janis Taube
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1025MO - Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors
Presenter: Thomas Marron
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1026MO - A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
Presenter: Luo Huiyan
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 1025MO and 1026MO
Presenter: María José De Miguel Luken
Session: Mini oral session - Investigational immunotherapy
Resources:
Slides
Webcast